Drug Eluting Articles & Analysis
9 articles found
In the dynamic landscape of modern medicine, technological advancements continuously reshape diagnostic and therapeutic approaches, fostering innovation and improving patient outcomes. Within this realm, the adoption of fluorinated ethylene propylene (FEP) and perfluoroalkoxy (PFA) tubing has emerged as a game-changer, revolutionizing various medical procedures across diverse specialties. Let's ...
This is a retrospective study of 111 patients with moderately to severely calcified lesions (MSCLs). Drug-eluting stents were implanted after rotational atherectomy and the mean follow-up was 382 days. ...
Background: This paper describes a challenging case of implantation of the EluNIR™ Ridaforolimus eluting elastomeric stent (Medinol Ltd.). This complex case involved a patient with a flow-limiting lesion in a native coronary artery post bypass surgery. The new EluNIR stent system includes a stent with a low metal footprint that comprises struts of variable width: ultra-narrow struts ...
ByMedinol
Incomplete stent expansion and malapposed stent struts are a predictor of subacute and late stent thrombosis. Appropriate lesion preparation prior to stent implantation is necessary to assure complete stent expansion and stent strut apposition. This is of particular importance in challenging lesions, in particular those with calcific plaque. The goal of the pre-dilatation is to obtain optimal ...
Incomplete stent expansion and malapposed stent struts are a predictor of subacute and late stent thrombosis. Appropriate lesion preparation prior to stent implantation is necessary to assure complete stent expansion and stent strut apposition. This is of particular importance in challenging lesions, in particular those with calcific plaque. The goal of the pre-dilatation is to obtain optimal ...
The dial-in numbers for the conference call are: SE: +46 856642651 PIN:19381497# UK: +44 3333000804 PIN:19381497# US: +1 6319131422 PIN:19381497# About BONESUPPORT™ BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting ...
About BONESUPPORT™ BONESUPPORT (Nasdaq Stockholm: BONEX) develops and commercializes innovative injectable bio-ceramic bone graft substitutes that remodel to the patient’s own bone and have the capability of eluting drugs. BONESUPPORT’s bone graft substitutes are based on the patented technology platform CERAMENT. ...
Some of these prior innovations that members of our leadership team were involved with include the Palmaz-Schatz balloon expandable coronary stent and the Cypher drug-eluting coronary stent. Now, our highly experienced leadership team has focused on solutions for the under-recognized and under-treated problems in the arterial and venous circulation, especially PE ...
Kum: Clinical trials for devices in this setting (eg, drug-eluting stents/balloons) for CLTI are difficult due to the complex nature of the patient and disease. ...